
EquitySector - HealthcareVery High Risk
Regular
NAV (16-Jan-26)
Returns (Since Inception)
Fund Size
₹587 Cr
Expense Ratio
2.28%
ISIN
INF251K01UY7
Minimum SIP
₹1,000
Exit Load
1.00%
Inception Date
27 Jun 2025
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
Since Inception
-6.54%
— (Cat Avg.)
| Equity | ₹559.99 Cr | 95.36% |
| Others | ₹27.25 Cr | 4.64% |
All Holdings
Equity
Debt & Others
| Name | Type | Amount | Holdings |
|---|---|---|---|
| Sun Pharmaceuticals Industries Ltd | Equity | ₹42.13 Cr | 7.17% |
| Mankind Pharma Ltd | Equity | ₹41.73 Cr | 7.11% |
| Cipla Ltd | Equity | ₹39.29 Cr | 6.69% |
| Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹34.49 Cr | 5.87% |
| Abbott India Ltd | Equity | ₹28.44 Cr | 4.84% |
| Apollo Hospitals Enterprise Ltd | Equity | ₹28.17 Cr | 4.80% |
| Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹27.76 Cr | 4.73% |
| Clearing Corporation Of India Ltd | Cash - Repurchase Agreement | ₹26.39 Cr | 4.49% |
| Lupin Ltd | Equity | ₹26.37 Cr | 4.49% |
| Divi's Laboratories Ltd | Equity | ₹25.57 Cr | 4.35% |
| Torrent Pharmaceuticals Ltd | Equity | ₹25.03 Cr | 4.26% |
| AstraZeneca Pharma India Ltd | Equity | ₹23.48 Cr | 4.00% |
| Ipca Laboratories Ltd | Equity | ₹20.72 Cr | 3.53% |
| Gland Pharma Ltd | Equity | ₹20.66 Cr | 3.52% |
| Ajanta Pharma Ltd | Equity | ₹20.59 Cr | 3.51% |
| ICICI Prudential Life Insurance Co Ltd | Equity | ₹19.38 Cr | 3.30% |
| Rainbow Childrens Medicare Ltd | Equity | ₹18.48 Cr | 3.15% |
| J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹18.2 Cr | 3.10% |
| Fortis Healthcare Ltd | Equity | ₹17.68 Cr | 3.01% |
| Laurus Labs Ltd | Equity | ₹16.62 Cr | 2.83% |
| Dr. Lal PathLabs Ltd | Equity | ₹14.83 Cr | 2.52% |
| Dr Reddy's Laboratories Ltd | Equity | ₹12.71 Cr | 2.17% |
| Medplus Health Services Ltd | Equity | ₹10.49 Cr | 1.79% |
| Emcure Pharmaceuticals Ltd | Equity | ₹10.23 Cr | 1.74% |
| Jupiter Life Line Hospitals Ltd | Equity | ₹6.27 Cr | 1.07% |
| Poly Medicure Ltd | Equity | ₹5.53 Cr | 0.94% |
| Metropolis Healthcare Ltd | Equity | ₹3.53 Cr | 0.60% |
| Nephrocare Health Services Ltd | Equity | ₹1.61 Cr | 0.27% |
| Net Receivables / (Payables) | Cash | ₹0.86 Cr | 0.15% |
Large Cap Stocks
35.32%
Mid Cap Stocks
29.11%
Small Cap Stocks
30.93%
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹540.61 Cr | 92.06% |
| Financial Services | ₹19.38 Cr | 3.30% |
Standard Deviation
This fund
--
Cat. avg.
15.84%
Lower the better
Sharpe Ratio
This fund
--
Cat. avg.
0.98
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.79
Higher the better

Since June 2025
ISIN INF251K01UY7 | Expense Ratio 2.28% | Exit Load 1.00% | Fund Size ₹587 Cr | Age 6 months | Lumpsum Minimum ₹1,000 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.

Total AUM
₹55,260 Cr
Address
Crescenzo, 7th Floor, G-Block, Mumbai, 400 051
Your principal amount will be at Very High Risk

Download Dezerv App
Track and monitor all
your investments